Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor

Total Page:16

File Type:pdf, Size:1020Kb

Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Gastroenterology 2020;158:1433–1449 Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice Prasad Dandawate,1 Gaurav Kaushik,2 Chandrayee Ghosh,1 David Standing,1 Afreen Asif Ali Sayed,1 Sonali Choudhury,1 Dharmalingam Subramaniam,1 Ann Manzardo,3 Tuhina Banerjee,4 Santimukul Santra,4 Prabhu Ramamoorthy,1 Merlin Butler,3 Subhash B. Padhye,1,5 Joaquina Baranda,6 Anup Kasi,6 Weijing Sun,6 Ossama Tawfik,7 Domenico Coppola,8 Mokenge Malafa,8 Shahid Umar,2 Michael J. Soares,7,9,10,11 Subhrajit Saha,12 Scott J. Weir,1,13 Animesh Dhar,1 Roy A. Jensen,1,7 Sufi Mary Thomas,1,14 and Shrikant Anant1,2,5 1Department of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas; 2Department of Surgery, University of Kansas Medical Center, Kansas City, Kansas; 3Department of Psychiatry and Behavioral Sciences, University of Kansas Medical Center, Kansas City, Kansas; 4Department of Chemistry, Pittsburg State University, Pittsburg, Kansas; 5Interdisciplinary Science and Technology Research Academy, Abeda Inamdar College, University of Pune, Pune; 6Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas; 7Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas; 8Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida; 9Department of Obstetrics and Gynecology, University of Kansas Medical Center, Kansas City, Kansas; 10Department of Pediatrics, University of Kansas Medical Center, Kansas City, Kansas; 11Center for Perinatal Research, Children’s Research Institute, Children’s Mercy–Kansas City, Kansas City, Missouri; 12Department of Radiation Oncology, University of Kansas Medical Center, Kansas City, Kansas; 13Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas; and 14Department of Otolaryngology, University of Kansas Medical Center, Kansas City, Kansas BASIC AND TRANSLATIONAL PANCREAS BACKGROUND & AIMS: Prolactin (PRL) signaling is up- compare levels of PRL and PRLR in multitumor tissue regulated in hormone-responsive cancers. The PRL receptor microarrays. We used structure-based virtual screening and (PRLR) is a class I cytokine receptor that signals via the Janus fragment-based drug discovery to identify compounds likely kinase (JAK)–signal transducer and activator of transcription to bind PRLR and interfere with its signaling. Human and mitogen-activated protein kinase pathways to regulate cell pancreatic cell lines (AsPC-1, BxPC-3, Panc-1, and MiaPaCa-2), proliferation, migration, stem cell features, and apoptosis. Pa- with or without knockdown of PRLR (clustered regularly tients with pancreatic ductal adenocarcinoma (PDAC) have high interspaced short palindromic repeats or small hairpin RNA), plasma levels of PRL. We investigated whether PRLR signaling were incubated with PRL or penfluridol and analyzed in contributes to the growth of pancreatic tumors in mice. proliferation and spheroid formation. C57BL/6 mice were METHODS: We used immunohistochemical analyses to given injections of UNKC-6141 cells, with or without Downloaded for Anonymous User (n/a) at University of Missouri Health Care from ClinicalKey.com by Elsevier on May 07, 2020. For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved. 1434 Dandawate et al Gastroenterology Vol. 158, No. 5 knockdown of PRLR, into pancreas, and tumor development WHAT YOU NEED TO KNOW was monitored for 4 weeks, with some mice receiving pen- fluridol treatment for 21 days. Human pancreatic tumor tis- BACKGROUND AND CONTEXT sues were implanted into interscapular fat pads of NSG mice, fl Prolactin signaling is upregulated in hormone-responsive and mice were given injections of pen uridol daily for 28 cancers, and patients with pancreatic ductal days. Nude mice were given injections of Panc-1 cells, xeno- adenocarcinoma (PDAC) have high plasma levels of graft tumors were grown for 2 weeks, and mice were then prolactin. The prolactin receptor (PRLR) signals via the given intraperitoneal penfluridol for 35 days. Tumors were JAK–STAT and MAPK pathways to regulate cell collected from mice and analyzed by histology, immunohis- proliferation, migration, stem-cell features, and apoptosis. tochemistry, and immunoblots. RESULTS: Levels of PRLR NEW FINDINGS were increased in PDAC compared with nontumor pancreatic tissues. Incubation of pancreatic cell lines with PRL activated Levels of PRLR are increased in PDAC, and exposure of signaling via JAK2–signal transducer and activator of tran- pancreatic cancer cells to PRL increases their scription 3 and extracellular signal–regulated kinase, as well proliferation and migration. Antipsychotic drugs such as penfluridol block PRLR signaling in pancreatic cancer as formation of pancospheres and cell migration; these ac- cells and reduced their proliferation, induced autophagy, tivities were not observed in cells with PRLR knockdown. and slowed growth of xenograft tumors in mice. Pancreatic cancer cells with PRLR knockdown formed significantly smaller tumors in mice. We identified several LIMITATIONS diphenylbutylpiperidine-class antipsychotic drugs as agents This study was performed in cell lines and mice. Studies in that decreased PRL-induced JAK2 signaling; incubation of humans are needed. pancreatic cancer cells with these compounds reduced their IMPACT proliferation and formation of panco spheres. Injections of 1 of these compounds, penfluridol, slowed the growth of Antipsychotic drugs such as penfluridol block JAK2 xenograft tumors in the different mouse models, reducing signaling in pancreatic cancer cells, slow tumor growth proliferation and inducing autophagy of the tumor cells. in mice, and might be tested in patients with PDAC. CONCLUSIONS: Levels of PRLR are increased in PDAC, and exposure to PRL increases proliferation and migration of cause of cancer-related deaths in the United States.11 Poor pancreatic cancer cells. Antipsychotic drugs, such as pen- prognosis, drug resistance, and high recurrence rates char- fluridol, block PRL signaling in pancreatic cancer cells to acterize PDAC after surgery.12 Here, we show that PRL in- reduce their proliferation, induce autophagy, and slow the duces both JAK2–STAT3 and extracellular signal–regulated growth of xenograft tumors in mice. These drugs might be kinase (ERK) signaling in the cells. PRLR knockdown tested in patients with PDAC. reduced the signaling and tumor growth in the orthotopic PDAC model, suggesting that PRLR may be an effective therapeutic target. To identify a small-molecule inhibitor, Keywords: Dopamine Receptor; Molecular Modeling; Combina- we developed an in silico model for the JAK2-interacting tion Therapy; Gemcitabine. domain and subsequently identified potential interacting diphenylbutylpiperidine (penfluridol, pimozide, fluspir- ilene) and phenothiazine (promethazine) antipsychotic TRANSLATIONAL PANCREAS rolactin (PRL) signaling has an established role in compounds. Using penfluridol as proof of principle, we maintaining pregnancy, mammary gland develop- show that it is effective in targeting PRLR signaling and BASIC AND P ment, immune regulation, adipocyte control, reproduction, suppressing tumor growth in the orthotopic PDAC model. and islet cell differentiation.1,2 Moreover, the pathway is Because penfluridol was initially identified as a dopamine implicated in multiple endocrine-driven tumors.3 More receptor D2 (DRD2) antagonist, we also determined recently, the pathway has been observed to play a role in whether its effect also occurs through DRD2. Although other tumor types, including colon and hepatocellular can- DRD2 expression is also induced in PDAC, the penfluridol cers.4,5 PRL receptor (PRLR) belongs to the class I cytokine effect on PDAC cells was not affected by DRD2 knockdown. fl receptor superfamily and lacks intrinsic kinase activity, This suggests that the pen uridol effect occurs through transducing signals including Janus kinase (JAK)–signal suppression of PRLR signaling. transducer and activator of transcription (STAT) and mitogen-activated protein kinase (MAPK) pathways through 6 Abbreviations used in this paper: AKT, protein kinase B; CRISPR, clus- kinases that interact with its cytoplasmic tail. The pathway tered regularly interspaced short palindromic repeats; DMEM, Dulbecco’s is implicated in the promotion of cell proliferation, migra- modified Eagle medium; DRD2, dopamine receptor D2; ERK, extracellular tion, stemness, and inhibition of apoptosis,7 as well as signal–regulated kinase; FBS, fetal bovine serum; JAK, Janus kinase; 8,9 MAPK, mitogen-activated protein kinase; mRNA, messenger RNA; PDAC, chemoresistance. In colon cancers, PRL induces JAK2– pancreatic ductal adenocarcinoma; PDX, patient-derived xenograft; PRL, STAT3 signaling to affect stemness by up-regulating the prolactin; PRLR, prolactin receptor; shRNA, short hairpin RNA; SPR, sur- 5 face plasmon resonance; STAT, signal transducer and activator of tran- Notch pathway. scription; TCGA, The Cancer Genome Atlas; TMA, tumor microarray. We now show that PRLR-based signaling is active in Most current article pancreatic ductal adenocarcinoma (PDAC). The reason for fi © 2020 by the AGA Institute choosing PDAC is 2-fold: rst, patients with PDAC have high 0016-5085/$36.00 10 plasma levels of PRL ; second, PDAC remains a leading https://doi.org/10.1053/j.gastro.2019.11.279 Downloaded
Recommended publications
  • Formulary (List of Covered Drugs)
    3ODQ<HDU 202 Formulary (List of Covered Drugs) PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THE FOLLOWING PLAN: $0 Cost Share AI/AN HMO Minimum Coverage HMO Silver 70 HMO Active Choice PPO Silver Opal 25 Gold HMO Silver 70 OFF Exchange HMO Amber 50 HMO Silver Opal 50 Silver HMO Silver 73 HMO Bronze 60 HDHP HMO Platinum 90 HMO Silver 87 HMO Bronze 60 HMO Ruby 10 Platinum HMO Silver 94 HMO Gold 80 HMO Ruby 20 Platinum HMO Jade 15 HMO Ruby 40 Platinum HMO This formulary was last updated on8//20. This formulary is VXEMHFWto change and all previous versions of the formulary no longer apply. For more recent information or other questions, please contact Chinese Community Health Plan Member Services at 1-888-775-7888 or, for TTY users, 1-877-681-8898, seven days a week from 8:00 a.m. to 8:00 p.m., or visit www.cchphealthplan.com/family-member -,-ϭ -,-ϭ"&* !#" + 5 5 ),-$+" %(%'.')/"+#" %&/"+ -%/"$)% "%&/"+ *& )&! %&/"+ 0 $(#" '"+ %&/"+ *& %&/"+ %&/"+ +)(2" &-%(.' %&/"+ +)(2" .1&-%(.' %&/"+ )&! .1&-%(.' !" .1&-%(.' dŚŝƐĨŽƌŵƵůĂƌLJǁĂƐůĂƐƚƵƉĚĂƚĞĚ8ͬϭͬϮϬϮϭ͘dŚŝƐĨŽƌŵƵůĂƌLJŝƐƐƵďũĞĐƚƚŽ ĐŚĂŶŐĞĂŶĚĂůůƉƌĞǀŝŽƵƐǀĞƌƐŝŽŶƐŽĨƚŚĞĨŽƌŵƵůĂƌLJŶŽůŽŶŐĞƌĂƉƉůLJ͘&ŽƌŵŽƌĞ ƌĞĐĞŶƚŝŶĨŽƌŵĂƚŝŽŶŽƌŽƚŚĞƌƋƵĞƐƚŝŽŶƐ͕ƉůĞĂƐĞĐŽŶƚĂĐƚŚŝŶĞƐĞŽŵŵƵŶŝƚLJ ,ĞĂůƚŚWůĂŶDĞŵďĞƌ^ĞƌǀŝĐĞƐĂƚϭͲϴϴϴͲϳϳϱͲϳϴϴϴŽƌ͕ĨŽƌddzƵƐĞƌƐ͕ ϭͲϴϳϳͲϲϴϭͲϴϴϵϴ͕ƐĞǀĞŶĚĂLJƐĂǁĞĞŬĨƌŽŵϴ͗ϬϬĂ͘ŵ͘ƚŽϴ͗ϬϬƉ͘ŵ͕͘ŽƌǀŝƐŝƚ ǁǁǁ͘ĐĐŚƉŚĞĂůƚŚƉůĂŶ͘ĐŽŵͬĨĂŵŝůLJͲŵĞŵďĞƌ !! %+)&,+ &%+&+&)$,#)0),# *+666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666I % + &%*6666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666I
    [Show full text]
  • Antipsychotics (Part-4) FLUOROBUTYROPHENONES
    Antipsychotics (Part-4) FLUOROBUTYROPHENONES The fluorobutyrophenones belong to a much-studied class of compounds, with many compounds possessing high antipsychotic activity. They were obtained by structure variation of the analgesic drug meperidine by substitution of the N-methyl by butyrophenone moiety to produce the butyrophenone analogue which has similar activity as chlorpromazine. COOC2H5 N H3C Meperidine COOC2H5 N O Butyrophenone analog The structural requirements for antipsychotic activity in the group are well worked out. General features are expressed in the following structure. F AR Y O N • Optimal activity is seen when with an aromatic with p-fluoro substituent • When CO is attached with p-fluoroaryl gives optimal activity is seen, although other groups, C(H)OH and aryl, also give good activity. • When 3 carbons distance separates the CO from cyclic N gives optimal activity. • The aliphatic amino nitrogen is required, and highest activity is seen when it is incorporated into a cyclic form. • AR is an aromatic ring and is needed. It should be attached directly to the 4-position or occasionally separated from it by one intervening atom. • The Y group can vary and assist activity. An example is the hydroxyl group of haloperidol. The empirical SARs suggest that the 4-aryl piperidino moiety is superimposable on the 2-- phenylethylamino moiety of dopamine and, accordingly, could promote affinity for D2 receptors. The long N-alkyl substituent could help promote affinity and produce antagonistic activity. Some members of the class are extremely potent antipsychotic agents and D2 receptor antagonists. The EPS are extremely marked in some members of this class, which may, in part, be due to a potent DA block in the striatum and almost no compensatory striatal anticholinergic block.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Repurposing Diphenylbutylpiperidine-Class Antipsychotic Drugs for Host
    bioRxiv preprint doi: https://doi.org/10.1101/2021.06.05.447191; this version posted June 6, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Repurposing diphenylbutylpiperidine-class antipsychotic drugs for host- 2 directed therapy of Mycobacterium tuberculosis and Salmonella enterica 3 infections 4 Heemskerk MT1, Korbee CJ1, Esselink J1, Carvalho dos Santos C1,2, van Veen S1, Gordijn IF1, 5 Vrieling F1, Walburg KV1, Engele CG1, Dijkman K3, Wilson L1, Verreck FAW3, Ottenhoff 6 THM1* and Haks MC1*. 7 1Department of Infectious Diseases, Leiden University Medical Center, Leiden, The 8 Netherlands. 2Laboratório Especial de Desenvolvimento de Vacinas, Instituto Butantan, São 9 Paulo, Brazil. 3TB research group, Department of Parasitology, Biomedical Primate Research 10 Centre, Rijswijk, The Netherlands. 11 * contributed equally. 12 13 14 15 Corresponding author: Tom HM Ottenhoff 16 Dept. of Infectious Diseases 17 Leiden University Medical Center (LUMC) 18 Albinusdreef 2 19 2333 ZA Leiden 20 The Netherlands 21 Tel: +31 71 526 2620 22 E-mail: [email protected] 23 ORCID ID: 0000-0003-3706-3403 24 25 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.06.05.447191; this version posted June 6, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.
    [Show full text]
  • Current Topics in Medicinal Chemistry, 2016, 16, 3385-3403 REVIEW ARTICLE
    Send Orders for Reprints to [email protected] 3385 Cur rent Topics in Medicinal Chemistry, 2016, 16, 3385-3403 REVIEW ARTICLE ISSN: 1568-0266 eISSN: 1873-5294 Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Impact Factor: 2.9 The international Present and Future journal for in-depth reviews on Current Topics in Medicinal Chemistry BENTHAM SCIENCE Peng Li*, Gretchen L. Snyder and Kimberly E. Vanover Intra-Cellular Therapies Inc, 430 East 29th Street, Suite 900, New York, NY 10016, USA Abstract: Schizophrenia is a chronic and debilitating neuropsychiatric disorder affecting approxi- mately 1% of the world’s population. This disease is associated with considerable morbidity placing a major financial burden on society. Antipsychotics have been the mainstay of the pharmacological treatment of schizophrenia for decades. The traditional typical and atypical antipsychotics demon- strate clinical efficacy in treating positive symptoms, such as hallucinations and delusions, while are A R T I C L E H I S T O R Y largely ineffective and may worsen negative symptoms, such as blunted affect and social withdrawal, as well as cognitive function. The inability to treat these latter symptoms may contribute to social Received: April 07, 2016 Revised: May 20, 2016 function impairment associated with schizophrenia. The dysfunction of multiple neurotransmitter Accepted: May 23, 2016 systems in schizophrenia suggests that drugs selectively targeting one neurotransmission pathway DOI: 10.2174/1568026616666160608 are unlikely to meet all the therapeutic needs of this heterogeneous disorder. Often, however, the un- 084834 intentional engagement of multiple pharmacological targets or even the excessive engagement of in- tended pharmacological targets can lead to undesired consequences and poor tolerability.
    [Show full text]
  • Central Nervous System (CNS) Agents
    Clinical Policy: Central Nervous System (CNS) Agents: Movement Disorders Reference Number: OH.PHAR.PPA.96 Effective Date: 01.01.2021 Last Review Date: 11.20 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. MOVEMENT DISORDERS CLINICAL PA REQUIRED “PREFERRED” PA REQUIRED “NON-PREFERRED” AUSTEDO ® (deutetrabenazine)† INGREZZA® (valbenazine) TETRABENAZINE (generic of Xenazine®) † Quantity limit of 4 tablets per day Description Deutetrabenazine (Austedo®), tetrabenazine (Xenazine®) and valbenazine (Ingrezza®) are vesicular monoamine transporter 2 (VMAT2) inhibitors. FDA Approved Indication(s) Austedo is indicated for the treatment of: • Chorea associated with Huntington’s disease • Tardive dyskinesia (TD) in adults Ingrezza is indicated for the treatment of adults with tardive dyskinesia. Xenazine is indicated for the treatment of chorea associated with Huntington’s disease. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with Centene Corporation® that Austedo, Xenazine or Ingrezza are medically necessary when the following criteria are met: I. Initial Approval Criteria A. Chorea Associated with Huntington Disease (must meet all): Page 1 of 7 CLINICAL POLICY Central Nervous System (CNS) Agents: Movement Disorders 1. Diagnosis of chorea associated with Huntington disease; 2. Requested medication is either Austedo or Xenazine; 3. Member must meet labeled age requirements for requested medication; 4. If requested medication is Austedo member has had a trial and failure of tetrabenazine at maximally tolerated doses up to 100 mg per day, unless contraindicated or clinically significant adverse effects are experienced; 5.
    [Show full text]
  • Cns Active Principles from Selected Chinese Medicinal Plants
    THE FACULTY OF MEDICINE IN THE UNIVERSITY OF LONDON CNS ACTIVE PRINCIPLES FROM SELECTED CHINESE MEDICINAL PLANTS Thesis presented by MIN ZHU (BSc., MSc.) for the degree of Doctor of Philosophy Department of Pharmacognosy The School of Pharmacy University of London 1994 ProQuest Number: 10105154 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest 10105154 Published by ProQuest LLC(2016). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 ABSTRACT In order to identify potential central nervous system (CNS) active principles from plants, 10 Chinese herbs have been selected from literature reports, namely Schejflera hodinieri, Schejflera delavayi, Celastrus angulatus, Celastrus orbiculatus, Clerodendrum mandarinorum, Clerodendrum bungei, Periploca callophylla, Periploca forrestii, Alangium plantanifolium and Uncaria rhynchophylla. These plants were extracted by 70% ethanol and biologically screened by receptor ligand binding assays which included a 1-adrenoceptor, a2-adrenoceptor, p-adrenoceptor, 5HT1, 5HT1A, 5HT1C, 5HT2, opiate, benzodiazepine, Ca^-ion channel(DHP), K^-ion channel, dopamine 1, dopamine 2, adenosine 1, muscarinic, histamine 1, Na'^/K^ ATPase, GABA^ and GABAg receptors. The results of extract screening showed that all these plants were able to inhibit the specific binding of radioligands to at least one receptor at concentrations of 1 mg/ml.
    [Show full text]
  • ERX.SPA.140 Tetrabenazine (Xenazine)
    Clinical Policy: Tetrabenazine (Xenazine) Reference Number: ERX.SPA.140 Effective Date: 03.01.15 Last Review Date: 05.21 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Tetrabenazine (Xenazine®) is a vesicular monoamine transporter 2 (VMAT) inhibitor. FDA Approved Indication(s) Xenazine is indicated for the treatment of chorea associated with Huntington’s disease. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. Health plan approved formularies should be reviewed for all coverage determinations. Requirements to use preferred alternative agents apply only when such requirements align with the health plan approved formulary. It is the policy of health plans affiliated with Envolve Pharmacy Solutions™ that Xenazine is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Chorea Associated with Huntington Disease (must meet all): 1. Diagnosis of chorea associated with Huntington disease; 2. Prescribed by or in consultation with a neurologist; 3. Age ≥ 18 years; 4. Targeted mutation analysis demonstrates a cytosine-adenine-guanine (CAG) trinucleotide expansion of ≥ 36 repeats in the huntingtin (HTT) gene; 5. Evidence of chorea is supported by a Unified Huntington Disease Rating Scale (UHDRS) score ranging from 1 to 4 on any one of chorea items 1 through 7 (see Appendix D); 6. Tetrabenazine is not prescribed concurrently with Austedo® or Ingrezza®; 7. Dose does not exceed 50 mg per day (100 mg per day if genotype testing confirms extensive or intermediate CYP2D6 metabolizer status).
    [Show full text]
  • WO 2019/094700 Al 16 May 2019 (16.05.2019) W 1P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2019/094700 Al 16 May 2019 (16.05.2019) W 1P O PCT (51) International Patent Classification: (72) Inventors: SANTOS, Michael; One Kendall Square, C07K 14/435 (2006.01) A01K 67/04 (2006.01) Building 200, Cambridge, Massachusetts 02139 (US). A01K 67/00 (2006.01) C07K 14/00 (2006.01) DELISLE, Scott; One Kendall Square, Building 200, Cam¬ A01K 67/033 (2006.01) bridge, Massachusetts 02139 (US). TWEED-KENT, Ailis; One Kendall Square, Building 200, Cambridge, Massa¬ (21) International Application Number: chusetts 02139 (US). EASTHON, Lindsey; One Kendall PCT/US20 18/059996 Square, Building 200, Cambridge, Massachusetts 02139 (22) International Filing Date: (US). PATTNI, Bhushan S.; 15 Evergreen Circle, Canton, 09 November 2018 (09. 11.2018) Massachusetts 02021 (US). (25) Filing Language: English (74) Agent: WARD, Donna T. et al; DT Ward, P.C., 142A Main Street, Groton, Massachusetts 01450 (US). (26) Publication Language: English (81) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of national protection available): AE, AG, AL, AM, 62/584,153 10 November 2017 (10. 11.2017) US AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 62/659,213 18 April 2018 (18.04.2018) US CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 62/659,209 18 April 2018 (18.04.2018) US DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 62/680,386 04 June 2018 (04.06.2018) US HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 62/680,371 04 June 2018 (04.06.2018) US KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (71) Applicant: COCOON BIOTECH INC.
    [Show full text]
  • Tardive Akathisia
    HEALTH & SAFETY: PSYCHIATRIC MEDICATIONS Tardive Akathisia FACT SHEET Tardive Akathisia BQIS Fact Sheets provide a general overview on topics important to supporting an individual’s health and safety and to improving their quality of life. This document provides general information on the topic and is not intended to replace team assessment, decision-making, or medical advice. This is the ninth of ten Fact Sheets regarding psychotropic medications. Intended Outcomes Individuals will understand the symptoms, common causes, and treatment of tardive akathisia. Definitions Akathisia: A movement disorder characterized by motor restlessness/a feeling of inner restlessness with a compelling need to be moving. Tardive akathisia: A severe prolonged form of akathisia which may persist after stopping the medica- tion causing the symptoms. Facts • Akathisia is: – the most common drug induced movement disorder. – a side effect of medication. – most often caused by antipsychotic medications that block dopamine. • Medications with akathisia as a potential side effect include: – Benzisothiazole (ziprasidone) – Benzisoxazole (iloperidone) – Butyrophenones (haloperidol, droperidol) – Calcium channel blockers (flunarizine, cinnarizine) – Dibenzazepine (loxapine, asenapine) – Dibenzodiazepine (clozapine, quetiapine) – Diphenylbutylpiperidine (pimozide) – Indolones (molindone) – Lithium – Phenothiazines (chlorpromazine, triflupromazine, thioridazine, mesoridazine, trifluoperazine, prochlorperazine, perphenazine, fluphenazine, perazine) Bureau of Quality Improvement
    [Show full text]
  • List of SSRI Effects Spirits for MD Widespread Use of Antidepressants
    List of SSRI Effects Spirits for MD widespread use of antidepressants in new SSRI-era, 2C family, 5-HT2Ay overactivity, 5-HT pro-drugs, abdominal distension, abnormal brain states, Abnormal Dreams, abnormal personalities, Abnormal Thinking, abnormally extreme emotions, abrupt cessation, abrupt interruption therapy, Acting aggressive, acting on dangerous impulses, active metabolite, acute pharma- cological action of meds, adaptation phase, & theory, addictions, Adhyperforin, adverse drug reaction, adverse effects, Advil, affect newborns, affect reuptake inhibition of serotonin & norepinephrine, aggression, aggressiveness, agitation, agomelatine, agoraphobia, akathisia, Alaproclate, alcohol use, alcohol Abuse, alcohol mixed with meds, alcoholism, Aleve, Allosteric serotonin reuptake inhibitor, alprazolam, altering hormones, alteration of neuronal activity in central nervous system, altered brain, altered mind, altered thinking, ambien, Amitifadine, amitriptyline, Amnesia, Amoxapine, Anafranil, analgesic, anorexia nervosa, anorgasmia, anti- depressant withdrawal aids, Anti-inflammatory, antiarrhythmic agents, antidepressant activity, Antidepressant Nightmares, antidepressant withdrawal symptoms, antidepressant-associated mania, antidepressant- associated psychosis, antidepressants, antipsychotic diphenylbutylpiperidine derivative, anxiety, anxiety related disorders, appetite changes, Aropax, arson, Asentra, Aspirin, ASA, Attempted Murder, Attempted suicide, auditory hallucinations, autism, autoimmune hypersensitivity, autonomic dysfunctions,
    [Show full text]
  • Tardive Dyskinesia
    Task Force Reports This is the eighteenth in a series of reports approved by the Board of Trustees of the American Psychiatric Association to give wider dissemination to the findings of APA's many commissions, committees, and task forces that are called upon to evaluate the state of the art in a problem area of current concern to the profession, to related disciplines, and to the public. The findings, opinions, and conclusions of the report do not necessarily represent the views of the officers, trustees, or all members of the Association. Each report, however, does represent the thoughtful judgment and findings of the task force of experts who composed it. These reports are considered a substantive contribution to the ongoing analysis and evaluation of problems, programs, issues, and practices in a given area of concern. Alan A. Stone, M.D. President, APA, 1979-80 Library of Congress Catalogue No. 80-65372 Copyright 1980 by the American Psychiatric Association 1400 K Street, N.W., Washington, D.C. 20005 Printed in U.S.A. 2nd Printing October, 1983 TARDIVE DYSKINESIA Report of the American Psychiatric Association Task Force on Late Neurological Effects of Antipsychotic Drugs Ross J. Baldessarini, M.D., Chairperson Jonathan O. Cole, M.D. John M. Davis, M.D. George Gardos, M.D., Consultant Sheldon H. Preskorn, M.D., Falk Fellow George M. Simpson, M.D. Daniel Tarsy, M.D., Invited Neurologist Approved for Publication by the Council on Research and Development John M. Davis, M.D., Chairperson Charles Gaitz, M.D. Edward Joel Sachar, M.D. George Winokur, M.D.
    [Show full text]